<DOC>
	<DOCNO>NCT01081145</DOCNO>
	<brief_summary>The primary objective study evaluate long-term maintenance efficacy Extended-Release Guanfacine HCl child adolescent ( 6-17 year ) attention-deficit/hyperactivity disorder ( ADHD ) respond initial open-label , short term treatment SPD503 .</brief_summary>
	<brief_title>Maintenance Efficacy Extended-Release Guanfacine HCl Children Adolescents With Attention-deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>1 . Male female , age 617 year time consent/assent Screening/Visit 1 . 2 . Subject 's parent legally authorise representative ( LAR ) must provide signature informed consent , must documentation assent ( applicable ) subject indicate subject aware investigational nature study require procedure restriction , accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guideline E6 ( 1996 ) applicable regulation complete studyrelated procedure Screening/Visit 1 . 3 . Subject meet DSMIVTR criterion primary diagnosis ADHD , combine subtype , hyperactive/impulsive subtype , inattentive subtype base detailed psychiatric evaluation use Kiddie Schedule Affective Disorders SchizophreniaPresent Lifetime version ( KSADSPL ) . 4 . Subject minimum ADHDRSIV total score 32 Enrolment/Visit 2 . 5 . Subject minimum CGIS score 4 Enrolment/Visit 2 . 6 . Subject function ageappropriate level intellectually , deem Investigator . 7 . Subject parent/LAR understand , willing , able , likely fully comply study requirement , procedure , restriction define protocol . 8 . Subject able swallow intact tablet . 9 . Subject female childbearing potential ( FOCP ) , define 9 year age &lt; 9 year age postmenarchal , must negative serum beta Human Chorionic Gonadotropin ( hCG ) pregnancy test Screening/Visit 1 negative urine pregnancy test Enrolment/Visit 2 agree comply applicable contraceptive requirement protocol . 10 . Subject supine stand BP measurement within 95th percentile age , gender , height . 1 . Subject current , control ( require prohibit medication behavioural modification program ) uncontrolled , comorbid psychiatric diagnosis , except oppositional defiant disorder ( ODD ) , include severe comorbid Axis II disorder severe Axis I disorder post traumatic stress disorder , bipolar illness , psychosis , pervasive developmental disorder , obsessivecompulsive disorder , substance abuse disorder , symptomatic manifestation lifetime history bipolar illness , psychosis , conduct disorder , opinion Investigator , contraindicate SPD503 treatment confound efficacy safety assessment . 2 . Subject condition illness include clinically significant abnormal Screening/Visit 1 laboratory value , opinion Investigator , represent inappropriate risk subject and/or could confound interpretation study . 3 . Subject known history presence structural cardiac abnormality , serious heart rhythm abnormality , syncope , cardiac conduction problem ( e.g. , clinically significant heart block ) , exerciserelated cardiac event include syncope pre syncope , clinically significant bradycardia . 4 . Subject orthostatic hypotension know history control uncontrolled hypertension . 5 . Subject clinically significant ECG finding judge Investigator consideration central ECG laboratory 's interpretation . 6 . Current use prohibit medication medication , include herbal supplement , affect BP heart rate CNS effect affect cognitive performance , sedate antihistamine decongestant sympathomimetics ( inhaled bronchodilator permit ) history chronic use sedate medication [ i.e. , antihistamine ] ) violation protocol specify washout criterion Enrolment/Visit 2 . 7 . Subject use investigational product within 30 day prior Enrolment/Visit 2 . 8 . Subject significantly overweight base Centre Disease Control Prevention Body Mass Index ( BMI ) forage gender specific chart . Significantly overweight define BMI &gt; 95th percentile . 9 . Children age 612 year body weight &lt; 25kg adolescent age 1317 year body weight &lt; 34kg &gt; 91kg Screening/Visit 1 . 10 . Subject know suspected allergy , hypersensitivity , clinically significant intolerance guanfacine hydrochloride component find SPD503 . 11 . Clinically important abnormality drug alcohol screen ( exclude subject 's current ADHD stimulant applicable ) Screening/Visit 1 . 12 . Subject history alcohol substance abuse dependence , define DSMIVTR ( exception nicotine ) within last 6 month . 13 . Subject female pregnant currently lactate . 14 . Subject fail screen previously enrol study . 15 . Subject currently consider suicide risk opinion Investigator , previously make suicide attempt , prior history , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment Investigator ( see protocol Section 7.2.4.2 additional guidance ) . 16 . History failure respond adequate trial alpha 2agonist treatment ADHD ( consist appropriate dose adequate duration therapy opinion Investigator ) . 17 . Subject history seizure disorder ( single childhood febrile seizure occur age 3 year ) presence serious tic disorder ( include Tourette 's syndrome ) . 18 . Subject another member household currently participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>